These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19668153)

  • 1. Brand biologics grab 12 years' exclusivity, for now.
    Osborne R
    Nat Biotechnol; 2009 Aug; 27(8):677-8. PubMed ID: 19668153
    [No Abstract]   [Full Text] [Related]  

  • 2. Data exclusivity for biologics.
    Grabowski H; Long G; Mortimer R
    Nat Rev Drug Discov; 2011 Jan; 10(1):15-6. PubMed ID: 21193860
    [No Abstract]   [Full Text] [Related]  

  • 3. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 4. Gearing up for follow-on biologics.
    Hughes B
    Nat Rev Drug Discov; 2009 Mar; 8(3):181. PubMed ID: 19247295
    [No Abstract]   [Full Text] [Related]  

  • 5. US biotech prepares to fight generic biologics.
    Reid B
    Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820
    [No Abstract]   [Full Text] [Related]  

  • 6. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 7. How Indian biotech is driving innovation.
    Nogrady B
    Nature; 2018 Dec; 564(7735):S53-S55. PubMed ID: 30542184
    [No Abstract]   [Full Text] [Related]  

  • 8. Follow-on biologics: data exclusivity and the balance between innovation and competition.
    Grabowski H
    Nat Rev Drug Discov; 2008 Jun; 7(6):479-88. PubMed ID: 18469828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obama budget aims to lower biologics exclusivity period.
    Future Med Chem; 2011 Mar; 3(4):395. PubMed ID: 21452975
    [No Abstract]   [Full Text] [Related]  

  • 10. 'Follow-on biologics': ensuring continued innovation in the biotechnology industry.
    Manheim BS; Granahan P; Dow KJ
    Health Aff (Millwood); 2006; 25(2):394-404. PubMed ID: 16610097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Market watch: Sales of biologics to show robust growth through to 2013.
    Goodman M
    Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 13. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 14. Market exclusivity for biologics.
    Wheadon DE
    N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
    [No Abstract]   [Full Text] [Related]  

  • 15. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing innovation, access, and profits--market exclusivity for biologics.
    Engelberg AB; Kesselheim AS; Avorn J
    N Engl J Med; 2009 Nov; 361(20):1917-9. PubMed ID: 19828525
    [No Abstract]   [Full Text] [Related]  

  • 17. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 18. World Generic Medicines Congress Americas--a Health Network Communications Conference. 18-21 November 2008, Washington DC, USA.
    Bowman M
    IDrugs; 2009 Feb; 12(2):92-4. PubMed ID: 19204881
    [No Abstract]   [Full Text] [Related]  

  • 19. Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.
    Lexchin J
    Value Health; 2017 Sep; 20(8):1139-1142. PubMed ID: 28964446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The market for follow-on biologics: how will it evolve?
    Grabowski H; Cockburn I; Long G
    Health Aff (Millwood); 2006; 25(5):1291-301. PubMed ID: 16966725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.